Biotech | October 15, 2021
Exelixis in-licenses second anti-cancer compound from Aurigene
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery
Harvard Medical School will deliver the first customized program, ‘Accelerate’, to create the next generation of leading experts in clinical development and medical affairs
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
The Pune centre expands its presence beyond Bangalore and Hyderabad
If authorized, molnupiravir could be the first oral antiviral medicine for the treatment of Covid-19
Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme
The company plans to expand its portfolio in regulated markets aggressively
Now all districts of the country will have commissioned PSA Oxygen plants
Subscribe To Our Newsletter & Stay Updated
